Topcon Acquires RetInSight to Expand AI Eye Care Tools

Topcon Healthcare has announced its acquisition of RetInSight, a Vienna, Austria-based AI company specializing in ophthalmic imaging analysis. The acquisition advances Topcon Healthcare’s strategic vision of “Healthcare from the Eye”, aiming to improve global access to intelligent diagnostics that enhance eye care delivery, reduce healthcare costs, and improve clinical outcomes.

AI Algorithms Supporting Early Detection and Monitoring of Retinal Diseases

RetInSight’s AI platform analyzes optical coherence tomography (OCT) images acquired during routine clinical care. Its suite of algorithms is designed to detect and monitor major retinal diseases, including:

• Geographic atrophy

• Wet age-related macular degeneration (AMD)

• Diabetic macular edema (DME)

• Retinal vein occlusion (RVO)

These tools support early intervention and personalized treatment planning, especially vital in aging populations where retinal conditions are increasingly prevalent.

Origin and Interoperability of RetInSight Technology

RetInSight’s platform originated from research conducted at the Medical University of Vienna’s Department of Ophthalmology and Optometry, led by Prof. Dr. Ursula Schmidt-Erfurth. The technology is already commercialized across Europe and is vendor-inclusive, meaning it supports interoperability with various OCT systems.

Leadership Commentary on Strategic Synergies

Prof. Hans Peter Schwarz, Chairman of the Board at RetInSight, expressed enthusiasm about the acquisition:

“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally. This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”

Ali Tafreshi, CEO and President of Topcon Healthcare, emphasized the strategic value of RetInSight’s expertise:

“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations. Integrated with our Harmony vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”

Broader Implications for Drug Development and Regulatory Progress

RetInSight’s AI algorithms are already used in pharmaceutical clinical trials and contribute to AI-powered drug development and regulatory pathways, including ongoing work to advance FDA clearances for U.S. indications.

Dr. Amir Sadeghipour, Managing Director of RetInSight, added:

“Together, we’re enabling seamless patient monitoring across the eye care continuum. This collaboration brings intelligent care to patients anywhere.”